NFKB1 and metabolic dysfunction-associated steatotic liver disease: Meanwhile, glucan-type LBP also could reduce the activation of the LPS/TLR4/NF-κB signaling pathway via downregulating the harmful bacteria Enterococcaceae and its metabolites, LPS, in HFD-induced NAFLD rats, thereby reducing liver inflammation and lesions [79].